US Patent 9856324 Human monoclonal antibodies to ganglioside GD2
Patent 9856324 was granted and assigned to Mabvax Therapeutics on January, 2018 by the United States Patent and Trademark Office.
All edits
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
US Patent 09856324 Human monoclonal antibodies to ganglioside GD2 US Patent 9856324 Human monoclonal antibodies to ganglioside GD2
US Patent 09856324 Human monoclonal antibodies to ganglioside GD2
Find more entities like US Patent 9856324 Human monoclonal antibodies to ganglioside GD2
